Moleculin Biotech Inc (MBRX): Next-Year EPS Estimate 64.18%
As of 2026-09-25, Moleculin Biotech Inc (MBRX) has a next-year EPS growth estimate of 64.18%. Featured in our EPS revision report on 2026-08-12.
On 2026-08-28, analyst consensus for MBRX's next-year EPS growth shifted from 42.10% to 64.18% — a positive change of 22.08 percentage points. The revised estimate has been sustained across 26 subsequent trading sessions. Current-year growth is projected at 88.51%.
What's Driving This
The primary driver of MBRX’s rise is a same-day upward revision to its next-year EPS growth estimate, raised from 42.10% to 64.18%. The catalyst plausibly connecting to that upgrade is Moleculin’s positive Phase 2/3 MIRACLE interim results, which reported annamycin complete remission rates three-fold greater than control, alongside its second-quarter
Generated 2026-09-08 from news as of 2026-09-08
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 64.18%
- EPS growth this year
- 88.51%
- EPS next quarter (est)
- -$0.44
- Last price
- $0.60
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-25 | 64.18% | 88.51% | -$0.44 | $0.60 |
| 2026-09-24 | 64.18% | 88.51% | -$0.44 | $0.57 |
| 2026-09-23 | 64.18% | 88.51% | -$0.44 | $0.53 |
| 2026-09-22 | 64.18% | 88.51% | -$0.44 | $0.56 |
| 2026-09-21 | 64.18% | 88.51% | -$0.44 | $0.52 |
| 2026-09-20 | 64.18% | 88.51% | -$0.44 | $0.77 |
| 2026-09-18 | 64.18% | 88.51% | -$0.44 | $0.77 |
| 2026-09-17 | 64.18% | 88.51% | -$0.44 | $0.78 |
| 2026-09-16 | 64.18% | 88.51% | -$0.44 | $0.74 |
| 2026-09-15 | 64.18% | 88.51% | -$0.44 | $0.75 |
| 2026-09-14 | 64.18% | 88.51% | -$0.44 | $0.78 |
| 2026-09-13 | 64.18% | 88.51% | -$0.44 | $0.71 |
| 2026-09-11 | 64.18% | 88.51% | -$0.44 | $0.71 |
| 2026-09-10 | 64.18% | 88.51% | -$0.44 | $0.83 |
| 2026-09-09 | 64.18% | 88.51% | -$0.44 | $0.76 |
| 2026-09-08 | 64.18% | 88.51% | -$0.44 | $0.75 |
| 2026-09-07 | 64.18% | 88.51% | -$0.44 | $0.71 |
| 2026-09-06 | 64.18% | 88.51% | -$0.44 | $0.71 |
| 2026-09-04 | 64.18% | 88.51% | -$0.44 | $0.71 |
| 2026-09-03 | 64.18% | 88.51% | -$0.44 | $0.68 |
| 2026-09-02 | 64.18% | 88.51% | -$0.44 | $0.69 |
| 2026-09-01 | 64.18% | 88.51% | -$0.44 | $0.65 |
| 2026-08-31 | 64.18% | 88.51% | -$0.44 | $0.64 |
| 2026-08-30 | 64.18% | 88.51% | -$0.44 | $0.65 |
| 2026-08-29 | 64.18% | 88.51% | -$0.44 | $0.65 |
| 2026-08-28 | 64.18% | 88.51% | -$0.44 | $0.65 |
| 2026-08-27 | 42.10% | 87.02% | -$0.65 | $0.69 |
| 2026-08-26 | 42.10% | 87.02% | -$0.65 | $0.60 |
| 2026-08-25 | 42.10% | 87.02% | -$0.65 | $0.61 |
| 2026-08-24 | 42.10% | 87.02% | -$0.65 | $0.61 |
Reports Featuring MBRX
Recent News
- Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE TrialGlobeNewswire
- MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of SignificanceStocktwits
- Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlGlobeNewswire
Screen Performance
Aggregate stats across all 2051 tickers our top-EPS-revision screen has flagged over the past 177 days.
- Median return since detection
- +0.0%
- % of tickers in the green
- 50%
- Median return on winners
- +22.6%
- Large revisions captured
- 1770
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Moleculin Biotech Inc's next-year EPS growth estimate?▾
As of 2026-09-25, Moleculin Biotech Inc (MBRX) has a next-year EPS growth estimate of 64.18%, based on analyst consensus.
When was the latest EPS estimate revision for MBRX?▾
The most recent revision occurred on 2026-08-28, when analysts adjusted the next-year EPS growth estimate from 42.10% to 64.18%.
What sector and industry does Moleculin Biotech Inc belong to?▾
Moleculin Biotech Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MBRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Moleculin Biotech Inc (MBRX) appears here because it was detected by our daily top-EPS-revision-performer screen.